{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:24:30Z","timestamp":1794057870360,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eprac.2026.09.117","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:16:05Z","timestamp":1791414965000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementing Metabolic Dysfunction\u2013Associated Steatotic Liver Disease Screening in Primary Care for Adults With Type 2 Diabetes: A Quality Improvement Initiative"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2838-789X","authenticated-orcid":false,"given":"Danielle Joyner","family":"Piekaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Kadar-Kricheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Evans","family":"Kreider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca Iris","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.eprac.2026.09.117_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","article-title":"Prevalence of steatotic liver disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020","volume":"22","author":"Kalligeros","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.eprac.2026.09.117_bib2","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.117_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cgh.2024.06.038","article-title":"Disparities for Hispanic adults with metabolic dysfunction-associated steatotic liver disease in the United States: a systematic review and meta-analysis","volume":"23","author":"Tesfai","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.117_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s10620-024-08722-0","article-title":"Disparities in metabolic dysfunction-associated steatotic liver disease prevalence, diagnosis, treatment, and outcomes: a narrative review","volume":"70","author":"Miller","year":"2025","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.eprac.2026.09.117_bib5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2026.09.117_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/00325481.2024.2325332","article-title":"Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting","volume":"136","author":"Allen","year":"2024","journal-title":"Postgrad Med"},{"issue":"4","key":"10.1016\/j.eprac.2026.09.117_bib7","article-title":"Embedding assessment of liver fibrosis into routine diabetic review in primary care","volume":"3","author":"Mansour","year":"2021","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.117_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"issue":"1 Suppl 1","key":"10.1016\/j.eprac.2026.09.117_bib9","first-page":"S59","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2026.09.117_bib10","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2026.09.117_bib11","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"17","key":"10.1016\/j.eprac.2026.09.117_bib12","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.3390\/jcm12175597","article-title":"Nonalcoholic fatty liver disease in patients with type 2 diabetes: screening, diagnosis, and treatment","volume":"12","author":"Ciardullo","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.eprac.2026.09.117_bib13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2337\/dc24-2075","article-title":"Screening for metabolic dysfunction-associated steatotic liver disease-related advanced fibrosis in diabetology: a prospective multicenter study","volume":"48","author":"Caussy","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.117_bib14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.14309\/ajg.0000000000003493","article-title":"Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicenter study","volume":"121","author":"Caviglia","year":"2026","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.117_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HEP.0000000000000351","article-title":"Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes","volume":"78","author":"Pennisi","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.117_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-10871-9","article-title":"MISHTI study evaluating hepatic fibrosis in type 2 diabetes patients in India","volume":"15","author":"Datta","year":"2025","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.eprac.2026.09.117_bib17","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jhep.2024.05.042","article-title":"Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort","volume":"81","author":"Oh","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.117_bib18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/hep4.1618","article-title":"Nonalcoholic fatty liver disease screening in type 2 diabetes mellitus patients in the primary care setting","volume":"5","author":"Vieira Barbosa","year":"2020","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.eprac.2026.09.117_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000024","article-title":"Prospective study of a case-finding algorithm to detect NAFLD with advanced fibrosis in primary care patients","volume":"7","author":"Fox","year":"2023","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.117_bib20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s13340-020-00453-7","article-title":"FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients","volume":"12","author":"Kawata","year":"2020","journal-title":"Diabetol Int"},{"issue":"12","key":"10.1016\/j.eprac.2026.09.117_bib21","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1136\/gutjnl-2023-330269","article-title":"Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial","volume":"72","author":"Zhang","year":"2023","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.eprac.2026.09.117_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16119","article-title":"Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care","volume":"45","author":"Younossi","year":"2025","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.eprac.2026.09.117_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.gtc.2019.09.006","article-title":"Recruitment and retention of patients for nonalcoholic steatohepatitis clinical trials","volume":"49","author":"DeLegge","year":"2020","journal-title":"Gastroenterol Clin North Am"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26012644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26012644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T12:39:12Z","timestamp":1794055152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26012644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"alternative-id":["S1530891X26012644"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.117","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementing Metabolic Dysfunction\u2013Associated Steatotic Liver Disease Screening in Primary Care for Adults With Type 2 Diabetes: A Quality Improvement Initiative","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.09.117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}